Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal
183.53
-4.52 (-2.40%)
Real-time:   10:27AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 183.05 - 189.72
52 week 136.37 - 203.30
Open 186.81
Vol / Avg. 346,434.00/1.39M
Mkt cap 36.39B
P/E 56.32
Div/yield     -
EPS 3.26
Shares 198.30M
Beta 0.72
Inst. own 98%
Apr 22, 2015
Q1 2015 Alexion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jan 29, 2015
Q4 2014 Alexion Pharmaceuticals Inc Earnings Call - Webcast
Jan 29, 2015
Q4 2014 Alexion Pharmaceuticals Inc Earnings Release
Jan 12, 2015
Alexion Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 25.58% 29.41%
Operating margin 33.98% 38.89%
EBITD margin - 41.00%
Return on average assets 15.20% 17.47%
Return on average equity 19.14% 23.11%
Employees 1,774 -
CDP Score - -

Address

352 Knotter Drive
CHESHIRE, CT 06410
United States - Map
+1-203-2722596 (Phone)
+1-203-2718198 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
David L. Hallal Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Senior Vice President
Age: 54
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 57
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Bio & Compensation  - Reuters
John B. Moriarty J.D. Senior Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Age: 44
Bio & Compensation  - Reuters
Frank J. Wright Senior Vice President; President of Alexion Pharma International Sarl
Age: 66
Bio & Compensation  - Reuters
R. Douglas Douglas Norby Lead Independent Director
Age: 78
Bio & Compensation  - Reuters